Strategic question
Which ventures have a proven, differentiated digital biomarker scoring algorithm in oncology?
How Galen Growth helped
From market signal to decision-ready evidence
Powered by HealthTech Alpha, we evaluated 110 ventures across eight priority markets, applied client criteria to build a prioritised list of 15, and mapped their strategic partnerships to pinpoint the most engagement-ready.
Outcomes
Replaced noisy marketing claims with a comparative, evidence-based view of who genuinely has the capability.
Decision enabled: Enabled the team to focus evaluation effort on the small number of ventures with defensible proof.
Key results
Our approach
A repeatable path to a defensible decision
Define
Clarify the strategic question, decision owner, market boundaries, and success criteria.
Map
Identify the relevant ventures, markets, competitors, partnerships, and evidence signals.
Assess
Evaluate maturity, traction, clinical relevance, commercial fit, and operational readiness.
Decide
Translate the evidence into a shortlist, benchmark, market view, or portfolio recommendation.
Related work
More digital health case studies
Tracking Competitor Moves to Support Global Franchise Strategy
How should we track competitor activity across obesity, diabetes and cardiovascular disease to support global strategic decisions?
Prioritising Markets and Partners to Accelerate a Women’s Health Roadmap
Which priority markets and venture partners should anchor our future women’s health innovation roadmap, starting with telemedicine?
Benchmarking Global Competitor Partnerships to Prioritise Digital Health Strategy
Where are competitors investing and partnering in Digital Health, and what should that mean for our own portfolio strategy?